Literature DB >> 14984396

Relapse prevention by citalopram in SAD patients responding to 1 week of light therapy. A placebo-controlled study.

K Martiny1, M Lunde, C Simonsen, L Clemmensen, D L Poulsen, K Solstad, P Bech.   

Abstract

OBJECTIVE: We have tested the relapse-preventive effect of citalopram when compared with placebo in 282 patients with Seasonal Affective Disorder (SAD) responding to 1 week of light therapy.
METHOD: The response rate to 1-week light therapy and relapse during the continuation phase of 15 weeks were assessed by use of the Hamilton Depression Rating Scale (HAM-D17), the six-item subscale (HAM-D6), the Melancholia Scale (MES), and the combined HAM-D/SIGH-SAD.
RESULTS: The response rate to light therapy was 62.5% on the HAM-D17 and the HAM-D6, 56.1% on the HAM-D/SIGH-SAD, 52.8% on the MES. In the continuation phase, citalopram was found superior to placebo on all scales, but the difference was only of statistical significance on the HAM-D6 and the MES. Mean citalopram dose was 26.3 mg.
CONCLUSION: Light therapy was found to have and early onset of action. On the HAM-D6 and the MES citalopram significantly reduced the relapse rate in the continuation phase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14984396     DOI: 10.1046/j.1600-0447.2003.00256.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  10 in total

1.  Second-generation antidepressants for preventing seasonal affective disorder in adults.

Authors:  Gerald Gartlehner; Barbara Nussbaumer-Streit; Bradley N Gaynes; Catherine A Forneris; Laura C Morgan; Amy Greenblatt; Jörg Wipplinger; Linda J Lux; Megan G Van Noord; Dietmar Winkler
Journal:  Cochrane Database Syst Rev       Date:  2019-03-18

2.  Validity of the definite and semidefinite questionnaire version of the Hamilton Depression Scale, the Hamilton Subscale and the Melancholia Scale. Part I.

Authors:  Jesper Bent-Hansen; Per Bech
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-03-02       Impact factor: 5.270

Review 3.  Citalopram versus other anti-depressive agents for depression.

Authors:  Andrea Cipriani; Marianna Purgato; Toshi A Furukawa; Carlotta Trespidi; Giuseppe Imperadore; Alessandra Signoretti; Rachel Churchill; Norio Watanabe; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 4.  Long-term and preventative treatment for seasonal affective disorder.

Authors:  Asa Westrin; Raymond W Lam
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features.

Authors:  Chi-Un Pae; Prakash S Masand; Kathleen Peindl; Paolo Mannelli; Changsu Han; David M Marks; Ashwin A Patkar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 6.  Treatment of seasonal affective disorder: unipolar versus bipolar differences.

Authors:  Chang-Ho Sohn; Raymond W Lam
Journal:  Curr Psychiatry Rep       Date:  2004-12       Impact factor: 8.081

7.  Augmentation of light therapy in difficult-to-treat depressed patients: an open-label trial in both unipolar and bipolar patients.

Authors:  Giovanni Camardese; Beniamino Leone; Riccardo Serrani; Coco Walstra; Marco Di Nicola; Giacomo Della Marca; Pietro Bria; Luigi Janiri
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-09       Impact factor: 2.570

8.  Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity.

Authors:  Jonathan Shelton; Sujin Yun; Susan Losee Olson; Fred Turek; Pascal Bonaventure; Curt Dvorak; Timothy Lovenberg; Christine Dugovic
Journal:  Front Behav Neurosci       Date:  2015-01-15       Impact factor: 3.558

Review 9.  Antidepressant chronotherapeutics for bipolar depression.

Authors:  Francesco Benedetti
Journal:  Dialogues Clin Neurosci       Date:  2012-12       Impact factor: 5.986

Review 10.  Seasonal affective disorder, winter type: current insights and treatment options.

Authors:  Ybe Meesters; Marijke Cm Gordijn
Journal:  Psychol Res Behav Manag       Date:  2016-11-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.